<DOC>
	<DOCNO>NCT01959321</DOCNO>
	<brief_summary>This multi-center observational study examines risk factor HCV transmission mother baby .</brief_summary>
	<brief_title>An Observational Study Hepatitis C Virus Pregnancy</brief_title>
	<detailed_description>This multi-center observational study examines risk factor HCV transmission mother baby . The study also assess risk factor associate Hepatitis C Virus ( HCV ) infection pregnant woman . Also , study describe outcome pregnant woman HCV well outcomes infant 18 month age . Approximately 750 HCV antibody positive pregnant woman infant follow baseline infant 18 month . A randomly select control cohort 500 pregnant woman HCV antibody negative follow delivery .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C Antibodies</mesh_term>
	<criteria>1 . Singleton pregnancy 2 . An HCV antibody positive screen ( case ) measure use two FDAapproved ELISA test , Abbott Architect version 3.0 system Ortho HCV 3.0 . 3 . Gestational age screening later 23 week 6 day , gestational age enrollment later 27 week 6 day , base clinical information evaluation early ultrasound describe . 1 . Eligible MaternalFetal Medicine Units ( MFMU ) Network Cytomegalovirus ( CMV ) trial ( positive CMV Immunoglobulin M ( IgM ) Immunoglobulin G ( IgG ) low avidity ) potentially eligible ( positive IgM , negative IgG ) 2 . Planned termination pregnancy 3 . Known major fetal anomaly demise 4 . Intention patient manage obstetrician delivery outside MFMU Network center , unless special provision make insure infant followup two 18 month age . 5 . Participation study previous pregnancy . 6 . Unwilling unable commit 18 month followup HCV positive infant</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>